Recruitment for the trial is set to commence in the third quarter of this year. Credit: Johnstocker Production / Shutterstock.com. The US Food and Drug Administration (FDA) has cleared Caliway ...

The study plans to enrol up to 12 patients. Credit: Chinnapong / Shutterstock.com. Kenai Therapeutics has dosed the first patient in its multi-centre Phase I REPLACE trial evaluating the allogeneic ...

Eli Lilly has now submitted a new drug application (NDA) for GLP-1RA orforglipron to the FDA for use in adults with obesity.

There have been several impactful clinical trial read outs in 2024. Image credit: Shutterstock / Rajitha Tennakoon From gene therapies to psychedelics and cancer vaccines to HIV pre-exposure ...

Recently, artificial intelligence (AI) has been paving the way and helping sponsors with patient identification and participant retention. Digital twins, a new technological frontier in the AI space, ...

The trial will enrol 300 chronic low back pain patients with inflammatory degenerative disc disease of less than five years duration. Credit: Anatoliy Cherkas / Shutterstock. Australia-based Mesoblast ...

The plan will launch a national standardised contract, simplifying paperwork and eliminating redundant technical assurances. Credit: Nanci Santos Iglesias / Shutterstock. The UK Government has ...

The Alzheimer’s disease market is expected to grow at a high compound annual growth rate (CAGR) of 21.8% from $2.4bn in 2023 to $17bn by 2033. Image credit: Antonio Marca / Shutterstock.com Eli Lilly ...

As patient-centricity is heavily discussed, the Clinical Trials Arena team investigates if this change is really happening. Image credit: Vitalii Vodolazskyi via Shutterstock Patient-centricity has ...

An expert from a CRO-SMO discusses Japan’s advantages as a clinical trial site. Credit: Athanasios Psimadis / Arena International Events. “Japan has the second biggest market for branded drugs and is ...

AI technology in clinical trials has the potential to speed up cohort selection and patient recruitment. However, data management and inherit bias in datasets need to be addressed first.

Currently, over 80 nations have approved AstraZeneca’s Tagrisso + chemotherapy based on the FLAURA2 trial data. Credit: T. Schneider / Shutterstock.com. AstraZeneca’s Tagrisso (osimertinib) combined ...